Sai Prasad N Iyer
Overview
Explore the profile of Sai Prasad N Iyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iyer S, Pino C, Yessayan L, Goldstein S, Weir M, Westover A, et al.
Transplant Direct
. 2024 May;
10(6):e1627.
PMID: 38769980
A stable, minimum physiological health status is required for patients to qualify for transplant or artificial organ support eligibility to ensure the recipient has enough reserve to survive the perioperative...
2.
Pitt B, Iyer S, Humes H
Eur J Heart Fail
. 2024 Feb;
26(3):534-536.
PMID: 38390738
No abstract available.
3.
Humes H, Goldstein S, Yessayan L, Catanzaro D, Scribe E, Iyer S, et al.
Crit Care Explor
. 2023 Oct;
5(10):e0995.
PMID: 37868028
Objectives: Acute kidney injury (AKI) requiring continuous kidney replacement therapy is a significant complication in ICU patients with mortality rates exceeding 50%. A dysregulated immune response can lead to systemic...
4.
Yessayan L, Humes H, Scribe E, Iyer S, Chung K
Nephron
. 2023 Jul;
148(1):43-53.
PMID: 37442112
Introduction: NEUTRALIZE-AKI is a pivotal study to evaluate the safety and effectiveness of the selective cytopheretic device (SCD) in adult patients with acute kidney injury (AKI) requiring continuous kidney replacement...
5.
Iyer S, Lee L, Li L
Physiol Rep
. 2020 Sep;
8(18):e14572.
PMID: 32965782
Currently described hyperkalemia (HK) animal models are typically acute and cause significant distress and mortality to the animals, warranting new approaches for studying chronic HK in a more appropriate clinical...
6.
Kang Y, Andjelic S, Binley J, Crooks E, Franti M, Iyer S, et al.
Vaccine
. 2009 Jul;
27(37):5120-32.
PMID: 19567243
SOSIP gp140 trimers represent a soluble, stabilized, proteolytically cleaved form of the HIV-1 envelope (Env) glycoproteins. SOSIP gp140 derived from a subtype A HIV-1 isolate, KNH1144, forms exceptionally stable trimers...
7.
Shan M, Klasse P, Banerjee K, Dey A, Iyer S, Dionisio R, et al.
PLoS Pathog
. 2007 Nov;
3(11):e169.
PMID: 17983270
The human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein gp120 is a vaccine immunogen that can signal via several cell surface receptors. To investigate whether receptor biology could influence immune...
8.
Iyer S, Franti M, Krauchuk A, Fisch D, Ouattara A, Roux K, et al.
AIDS Res Hum Retroviruses
. 2007 Jul;
23(6):817-28.
PMID: 17604546
HIV type 1 (HIV-1) envelope is a noncovalent trimer of gp120-gp41 heterodimers, and its lability has hindered structural studies. SOSIP gp140 is a soluble, proteolytically mature form of the HIV-1...
9.
Beddows S, Franti M, Dey A, Kirschner M, Iyer S, Fisch D, et al.
Virology
. 2006 Nov;
360(2):329-40.
PMID: 17126869
The human immunodeficiency virus type 1 (HIV-1) surface envelope glycoprotein (Env) complex, a homotrimer containing gp120 surface glycoprotein and gp41 transmembrane glycoprotein subunits, mediates the binding and fusion of the...
10.
Beddows S, Kirschner M, Campbell-Gardener L, Franti M, Dey A, Iyer S, et al.
AIDS Res Hum Retroviruses
. 2006 Jun;
22(6):569-79.
PMID: 16796532
The generation of an antibody response capable of neutralizing a broad range of clinical isolates remains an important goal of human immunodeficiency virus type 1 (HIV-1) vaccine development. Envelope glycoprotein...